Allena Pharmaceuticals

$1.81
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.17 (+10.37%) Today
$0.00 (0.00%) As of 10:14 PM UTC after-hours

Why Robinhood?

You can buy or sell ALNA and other stocks, options, and ETFs commission-free!

About ALNA

Allena Pharmaceuticals, Inc. Common Stock, also called Allena Pharmaceuticals, is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA. The listed name for ALNA is Allena Pharmaceuticals, Inc. Common Stock.

CEO
Louis Brenner
Employees
83
Headquarters
Newton, Massachusetts
Founded
2011
Market Cap
96.51M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.18M
High Today
$1.84
Low Today
$1.71
Open Price
$1.75
Volume
940.30K
52 Week High
$3.39
52 Week Low
$0.525

ALNA Earnings

-$0.57
-$0.38
-$0.19
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, Pre-Market

You May Also Like

DCOM
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure